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NOTES

Judging GINA
DOES THE GENETIC INFORMATION
NONDISCRIMINATION ACT OF 2008 OFFER
ADEQUATE PROTECTION?
INTRODUCTION
With the advancement of medicine and technology in
genetics, new forms of discrimination have emerged in both the
healthcare system and the workplace. In an attempt to
minimize the costs associated with insurance premiums and
sick leave, some employers have chosen to terminate employees
who are genetically predisposed to certain conditions.1 For
example, Kim, a social worker, mentioned to her co-workers
that she had cared for her mother who passed away from
Huntington’s disease.2 Due to the genetic nature of the illness,
this passing comment indicated that Kim had a 50% chance of
also developing the debilitating disorder.3 Despite her record of
strong job performance, Kim was discharged from her position
only a week after her revelation.4 For Gary, his employer
administered secret genetic testing in an attempt to determine
which employees were genetically predisposed to developing
Carpal Tunnel Syndrome.5 When Gary refused to partake in
the genetic screening, his employer initiated disciplinary
1

Rivka Jungreis, Note, Fearing Fear Itself: The Proposed Genetic
Information Nondiscrimination Act of 2005 and Public Fears About Genetic
Information, 15 J.L. & POL’Y 211, 218 (2007).
2
NAT’L P’SHIP FOR WOMEN & FAMILIES ON BEHALF OF THE COAL. FOR
GENETIC FAIRNESS, FACES OF GENETIC DISCRIMINATION: HOW DISCRIMINATION
AFFECTS REAL PEOPLE 5 (2004), available at http://www.nationalpartnership.org/
site/DocServer/FacesofGeneticDiscrimination.pdf.
3
Id.
4
Id.
5
Id.
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proceedings to terminate his employment.6 Likewise, though
David has an approximately 16% chance of having a cancerous
genetic mutation,7 he is waiting for discrimination protection
before taking the necessary test.8 Not surprisingly, for many
Americans, there is a growing wariness toward genetic
screening out of fears of discrimination in the work place.
The nationwide fear of genetic testing has detrimental
consequences not only for the physical health of individuals,
but also for scientific development.9 Without participants to
enroll in genetic studies, researchers cannot improve the
accuracy of genetic screening, since large data pools are often
required to link gene variants to health conditions.10 In
addition, individuals put their physical well-being at risk by
foregoing the opportunity to take additional measures to
monitor or avoid conditions for which they are genetically
predisposed.11 In one frightening situation, the parents of a
young girl learned that their family had a history of a Factor V
Leiden mutation, a condition associated with a heightened risk
for blood clots.12 The family was advised to wait until Congress
passed legislation protecting against genetic discrimination
before testing their daughter for the mutation.13 As a result of
waiting, their daughter nearly died after suffering a massive
blood clot.14
In response to the growing concern about genetic
discrimination in the workplace,15 Congress passed the Genetic
Information Nondiscrimination Act of 2008 (“GINA”).16
Arguably, this new legislation will allow Americans to take
greater advantage of genetic testing opportunities and to
6

Id.
Malorye
Allison,
Industry
Welcomes
Genetic
Information
Nondiscrimination Act, 26 NATURE BIOTECHNOLOGY 596, 597 (2008).
8
Id.
9
Susannah Baruch & Kathy Hudson, Civilian and Military Genetics:
Nondiscrimination Policy in a Post-GINA World, 83 AM. J. HUM. GENETICS 435, 436
(2008).
10
Id.
11
Id.
12
Id.
13
Id.
14
Id.
15
Kathy L. Hudson et al., Keeping Pace with the Times—The Genetic
Information Non-discrimination Act of 2008, 358 NEW ENG. J. MED. 2661, 2661 (2008);
Anne Bond Emrich, New Law Will Protect Genetic Information, GRAND RAPIDS BUS. J.,
Oct. 29, 2008, at S9.
16
IOMA, Employer Advocates Remain Wary of Genetic Bias Law’s Potential
Effects, 8 MANAGING BENEFITS PLANS 1, 1 (2008) [herinafter Employer Advocates].
7

2009]

JUDGING GINA

547

receive more personalized medical care.17 For health insurance
providers, GINA bars the use of an applicant’s genetic
information when making policy enrollment or coverage
decisions.18 Furthermore, the Act addresses potential genetic
discrimination in the workplace by prohibiting employers from
using genetic information when making decisions related to the
terms and conditions of employment.19
This Note argues that GINA was a necessary law in
light of this country’s history of discrimination on the basis of
genetic information. Since prior federal laws, such as the
Americans
with
Disabilities
Act
(the
“ADA”), Title VII of the Civil Rights Act of 1964 (the “Civil
Rights Act”), and the Health Insurance Portability and
Accountability Act of 1996 (“HIPAA”) do not adequately protect
employees from genetic discrimination, GINA now offers relief
to employees who fall victim to discrimination based on a
predisposition to a genetic disease. However, this legislation is
only the first step in preventing discrimination by employers
using genetic information. Indeed, the bill has not gone far
enough to protect individuals and their families. Consequently,
as science and technology continue to advance, amendments to
GINA will be needed in order to provide full protection to
affected individuals.
Part I of this Note presents a basic overview of genetic
testing. Part II examines the historical background of GINA
with specific instances of genetic discrimination as well as
quantitative evidence of the current fear of discrimination
based on genetic predisposition to an illness. In addition, Part
II examines the gaps in federal legislation prior to GINA and
argues that the ADA, Title VII, and HIPAA did not provide
adequate protection from discrimination based on one’s genes.
Part III of this Note describes the scope of protection provided
to employees by GINA. Finally, Part IV concludes that GINA
fails to fully address the issue of genetic discrimination in the
workplace, and, as such, additional protections are required.

17

Emrich, supra note 15.
COALITION FOR GENETIC FAIRNESS, WHAT DOES GINA MEAN?: A GUIDE TO
THE GENETIC INFORMATION NONDISCRIMINATION ACT 3, 7 (2008), available at
http://www.geneticfairness.org/GINAPublication111008.pdf.
19
Id. at 3, 9.
18
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A BRIEF INTRODUCTION TO GENETIC TESTING

Genetic testing is an advanced method of diagnosis
made available by the completion of the Human Genome
Project.20 Simply put, a gene is a segment of DNA that stores
our hereditary information in cells.21 Through genes, parents
pass biological information and physical traits such as hair
color and height to their children.22 In particular, genes contain
the “recipes” for protein creation and “supply the structural
components of all our cells and tissues as well as specialized
enzymes for all essential chemical reactions.”23 These proteins
enable genes to determine how well our bodies function and
interact with the environment, for example, fighting infections
and processing food.24 It is estimated that each person has
anywhere from 20,000-25,000 genes.25
The unit of information in DNA is the “base,” which is
composed of adenine, thymine, cytosine, or guanine—“A,” “T,”
“C,” or “G,” respectively.26 In any two individuals, the base
sequence is estimated to be at least 99% identical.27 Variation
in DNA sequence accounts for some physical differences
between people, and, in some cases, for differences in
susceptibility to disease.28 Rare sequence variations, called
20

Hudson et al., supra note 15, at 2661. The Human Genome Project was
completed in 2003. Id.
21
Denise Casey, What Can the New Gene Tests Tell Us? 36 JUDGES’ J. 14, 1415 (1997), available at http://www.ornl.gov/sci/techresources/Human_Genome/publicat/
judges/judge.html (“In humans and other higher organisms, a DNA molecule consists of
two ribbon-like strands that wrap around each other, resembling a twisted ladder. The
ladder rungs are made up of chemicals called bases, abbreviated A, T, C, and G. Each
rung consists of a pair of bases, either A and T or C and G. We have three billion base
pairs (six billion bases) of DNA in most of our cells; this is our genome. With the
exception of identical twins, the sequence of the bases—the order of As, Ts, Cs, and
Gs—is different for everyone, which is what makes each of us unique. Variation in base
sequence, along with environmental factors, accounts for all our diversity, including
disease.”).
22
Paul Steven Miller, Is There a Pink Slip in my Genes? Genetic
Discrimination in the Workplace, 3 J. HEALTH CARE L. & POL’Y 225, 228 (2000).
23
Casey, supra note 21, at 14.
24
Id.
25
Human Genome Program, U.S. Dep’t Energy, Human Genome Project
Information, http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml (last
visited Jan. 16, 2010); Better Health Channel, Genes and Genetics,
http://www.betterhealth.vic.gov.au/bhcv2/bhcarticles.nsf/pages/Genes_and_genetics
(last visited Jan. 16, 2010).
26
Genetics Home Reference, What is DNA?, http://ghr.nlm.nih.gov/handbook/
basics/dna (last visited Jan. 16, 2010).
27
Id.
28
Casey, supra note 21, at 16.
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mutations, can vastly increase the risk of certain diseases by
producing “faulty proteins that function at less-than-normal
levels or those that are completely nonfunctional . . . .”29
The Human Genome Project enabled scientists to search
for genes associated with diseases such as cystic fibrosis and
Huntington’s disease.30 By far, the most immediate and
practical application to come out of the Project was the genetic
test, which inspects “DNA sample[s] for mutated sequences.”31
Today, over 1,100 genetic tests are available which can be used
for carrier testing, prenatal genetic testing, preimplantation
genetic testing, newborn genetic screening, genome scanning,32
“presymptomatic testing for predicting adult-onset disorders
such as Huntington’s disease, presymptomatic testing for
estimating the risk of developing adult-onset cancers and
Alzheimer’s disease, confirmational diagnosis of a symptomatic
individuals, and forensic/ identity testing.”33
Diagnostic testing explains why a person has symptoms
of a disease and can also be used to confirm a diagnosis based
on these symptoms.34 Whereas presymptomatic testing can
determine whether a person at risk for a disease such as
Huntington’s has actually inherited the corresponding gene,35
predictive testing can be used to determine whether a person
not known to be at risk is in fact likely to develop a genetically
based disease, such as particular forms of cancers.36 For
parents, carrier testing can determine whether a person carries

29

Id. “Sometimes only a tiny change in DNA sequence will lead to a serious
disease. The substitution of just a single base, for example, leads to sickle cell
anemia. . . . Too many repetitions of a particular sequence of three DNA bases can
doom a person to Huntington’s disease, a fatal neurological disorder; Fragile X
syndrome, the most common form of inherited mental retardation; or myotonic
dystrophy, a muscle-wasting disease.” Id.
30
Id. at 18.
31
Human Genome Program, U.S. Dep’t Energy, Gene Testing,
http://www.ornl.gov/sci/techresources/Human_Genome/medicine/genetest.shtml
(last
visited Jan. 16, 2010). “For some types of gene tests, researchers design short pieces of
DNA called probes, whose sequences are complementary to the mutated sequences.
These probes will seek their complement among three billion pairs of an individual’s
genome. If the mutated sequence is present in the patient’s genome, the probe will bind
to it and flag the mutation.” Id.
32
Id.
33
Casey, supra note 21, at 17.
34
NIH, U.S. Dep’t Health & Human Servs., Genetics Home Reference, What
are the Types of Genetic Tests?, http://ghr.nlm.nih.gov/handbook/testing/uses (last
visited Jan. 16, 2010).
35
Id.
36
Id.
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a gene that, if passed to a child, will result in disease.37 These
tests can help people make informed choices about their
personal health. However, evidence demonstrates that many
Americans avoid taking advantage of these scientific
developments for fear that non-favorable results could lead to
discrimination by their employers, insurers, or healthcare
providers.38
II.

LEGISLATIVE BACKGROUND OF THE GENETIC
INFORMATION NONDISCRIMINATION ACT OF 2008

Senator Edward Kennedy of Massachusetts proclaimed
that the Genetic Information Nondiscrimination Act of 2008
was “the first major new civil rights bill of the new century.”39
Passage of this bill was no easy feat, and required thirteen
years of congressional debate regarding the need for federal
legislation to prevent abuse of individuals’ genetic
information.40 Throughout the debate, insurers and employers
argued that existing laws provided adequate protection for
individuals and that the passage of GINA would only create
confusion and unnecessary costs.41 Furthermore, opponents
expressed concern that the act was overly broad and that its
definition of “genetic information” would require employers to
provide health coverage for far too many genetic disorders.42 In
addition, some challenged the bill on the basis that genetic
discrimination did not occur in the workplace, as evidenced by
the limited number of documented cases.43 Likewise, employers
maintained that in some situations access to genetic
information is crucial to make important employment

37

Id.
Lauren J. Sismondo, GINA, What Could You Do for Me One Day?: The
Potential of the Genetic Information Nondiscrimination Act to Protect the American
public, 21 WASH. U. J.L. & POL’Y 459, 464 (2006); Ellen Wright Clayton, Ethical, Legal,
and Social Implications of Genome Medicine, 349 NEW ENG. J. MED. 562, 562 (2003).
39
Hudson et al., supra note 15, at 2662.
40
Id. at 2661.
41
Lauren
Elizabeth
Nuffort,
Note,
The
Genetic
Information
Nondiscrimination Act of 2008: Raising a Shield to Genetic Discrimination in
Employment and Health Insurance. 21 HEALTH L. 1, 10-11 (2009).
42
Patricia Alten, Note, GINA: A Genetic Information Nondiscrimination
Solution in Search of a Problem, 61 FLA. L. REV. 379, 389 (2009); Nuffort, supra note
41, at 11.
43
Hon. Louise McIntosh Slaughter, Genetic Testing and Discrimination: How
Private is Your Information?, 17 STAN. L. & POL’Y REV. 67, 78 (2006); Nuffort, supra
note 41, at 11.
38
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decisions.44 These companies argued that access to such
information allows them to both lower the potential costs
associated with excessive sick leave as well as avoid the higher
costs from potential increases in insurance claims from
employees likely to become sick in the future.45 However, these
arguments were refuted by a long history of discrimination in
the workplace made possible by employers’ unregulated access
to employees’ genetic information. As a result, Congress
determined that despite the potential for increases in litigation
and employer costs, GINA was an absolutely necessary law.46
A.

Genetic Discrimination of Racial and Ethnic Groups

Long before the completion of the Human Genome
Project and the resulting easy accessibility of genetic
information, Americans still had reason to fear employment
discrimination on the basis of their genes. In the early 1970s,
scientists discovered a gene linked with sickle cell anemia—a
blood disorder which is found in individuals of sub-Saharan
African descent more commonly than other races.47 In response
to this discovery, many states mandated sickle cell anemia
screening for African-Americans.48 Later, researchers issued
reports that those carrying the diseased gene might be more
vulnerable to workplace toxins.49 While the mandatory testing
policies were originally intended to merely identify carriers and
thus offer prenatal testing, the results were not kept
confidential and were ultimately used in a discriminatory
manner.50 Healthy carriers of the gene suffered adverse
employment actions, and a false stigma developed that AfricanAmericans were inherently more susceptible to genetic disease
than individuals of other races.51 In 1972, Congress responded
by passing the National Sickle Cell Anemia Control Act, which

44

Nuffort, supra note 41, at 11.
Id.
46
Daniel Schlein, New Frontiers for Genetic Privacy Law: The Genetic
Information Nondiscrimination Act of 2008, 19 GEO. MASON U. CIV. RTS. L.J. 311, 351
(2009).
47
Jungreis, supra note 1, at 228.
48
Christine
Formas
Norris,
Note,
The
Genetic
Information
Nondiscrimination Act of 2008: History, Successes, and Future Considerations, 7 U.
MD. L.J. RACE, RELIGION, GENDER & CLASS 192, 201 (2007).
49
Jungreis, supra note 1, at 228.
50
Id. at 228-29.
51
Norris, supra note 48, at 201.
45
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banned states from federal funds unless their mandated sickle
cell screening programs were made voluntary.52
Like African-Americans, people of Ashkenazi (Eastern
European) Jewish descent have also feared discriminatory
treatment for their susceptibility as a group to certain genetic
characteristics such as Tay-Sachs disease, as well as breast,
colon, and ovarian cancers.53 As a result, in the 1980s, Rabbi
Joseph Eckstein created an organization called Dor Yeshorim
to prevent recessive genetic diseases from being passed from
one generation to the next.54 This program screens Hasidic
youths and informs them of their genetic compatibility with
potential partners to prevent marriage and procreation among
individuals possessing the genes for various diseases.55 In
addition to preventing the tragedy of a child born with a lifethreatening genetic disorder, the program is also designed to
“avoid the risk of stigmatizing . . . young single[s] . . . [and]
their family members.”56 While this program may have sought
to provide protection, in effect it has contributed to the
stigmatization of individuals based on their genetic
predispositions.
B.

Fears of Genetic Information in the Workplace—
Quantitative Evidence

The most common concern among those who seek
genetic testing is that the results will be used in some harmful
way, typically either by denial of health insurance or by
discrimination with regard to hiring or firing decisions.57 In
1998, the federal government funded a national survey in
conjunction with the National Center for Genome Resources to
discern the public’s attitude regarding the emerging
availability of genetic testing.58 Of the 1,000 people polled, 85%
indicated that they did not want employers to have access to
test results, and 27% answered that they would not be willing

52

Id.
Janet L. Dolgin, Personhood, Discrimination, and the New Genetics, 66
BROOK. L. REV. 755, 789 (2001).
54
The Shidduch Site, Medical Issues (The Shidduch Site) Jewish Genetic
Diseases, http://www.shidduchim.info/medical.html (last visited Jan. 16, 2010).
55
Slaughter, supra note 43, at 69.
56
The Shidduch Site, supra note 54.
57
Clayton, supra note 38, at 562.
58
Miller, supra note 22, at 232.
53
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to take a genetic test if their employer could subsequently
retrieve their results.59
Although many people desire genetic testing for cancer,
a large number clearly fear potential discrimination based on
the outcome.60 In 1999, the Yale Cancer Center surveyed 300
active cancer genetic counselors and found that 85% would test
for the breast cancer gene mutation and 91% would test for the
hereditary nonpolyposis colon cancer gene mutation.61 However,
68% of those surveyed indicated that they would not submit the
charges of these screenings to their healthcare providers, and
26% claimed that they felt compelled to use a false name.62
Similarly, the U.S. Department of Labor also discovered that
many women do not partake in breast cancer screening due to
a fear of stigmatization if the results are made available to
their employers.63
Recently, the American Management Association (the
“Association”) has found that employers have engaged in
discriminatory practices toward healthy employees found to be
genetically predisposed to certain diseases.64 Importantly, the
Association reported that employers have accessed their
workers’ genetic information in the following ways: “one
percent was conducting genetic tests for Sickle Cell Anemia,
0.4 percent was testing for Huntington’s disease . . . [f]ourteen
percent were conducting workplace susceptibility testing which
surveyors acknowledged might include genetic testing, . . . [and
t]wenty percent were requesting family medical histories.”65 In
2007, the American Journal of Human Genetics reported that
three-quarters of their survey respondents desired a federal
law that would thwart employers from making hiring and

59

Id. at 232-33. A similar study was conducted by Georgetown University in
1995. Researchers discovered there that “[w]orker’s fears of workplace
discrimination . . . have prevented one out of ten respondents from getting tested for
genetic traits linked to breast cancer, cystic fibrosis, Huntington’s Disease, colon
cancer, or other conditions, even though early detection and treatment could possibly
improve their lives.” Id. at 234.
60
Yale Cancer Center Study Underscores Fear of Discrimination Over Genetic
Testing, SCI. DAILY, Oct. 25, 1999, http://www.sciencedaily.com/releases/1999/10/
991025075308.htm.
61
Id.
62
Id. In addition, “82% of counselors said that if tested positive, they would
share the results with their physicians, but many would not want their carrier status
documented in their medical records.” Id.
63
Miller, supra note 22, at 234.
64
Norris, supra note 48, at, 197-98.
65
Id.
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firing decisions based on the respondents’ genetic likelihood of
developing a disease in the future.66
From these survey results, it is clear that fear of
discrimination flowing from genetic testing hinders the use of
screening technologies. Consequently, this fear has serious
implications for the overall health and well-being of individuals
who avoid genetic screening programs that could be beneficial
to their health.67 In addition to individual concerns, the
reluctance to utilize genetic testing raises serious social policy
concerns. Most significantly, further scientific advancement
relies on willing participants in clinical research.68 If people are
unwilling to partake in genetic studies, this may hinder the
development of new genetic tests and may even inhibit the
discovery of new treatments for genetic diseases.69 This popular
reluctance to genetic profiling creates difficulties for scientists
who propose “massive population-based studies that will enable
them to identify and distinguish genetic, environmental, and
lifestyle-based contributors to disease.”70
C.

Judicial Application of Prior Legislation to Genetic
Discrimination Cases

Prior to the enactment of GINA, no federal law existed
that specifically protected against workplace discrimination
based on a genetic predisposition to certain diseases.71 Although
minimal safeguards were given under the Americans with
Disabilities Act and Title VII of the Civil Rights Act of 1964,
these statutes were not extended to fully protect employees
from discrimination based on their genetic profile.72 Further,
some relief was made available to employees under federal
privacy laws and via the Health Insurance Portability and
Accountability Act of 1996.73 A presidential executive order and
many state laws were also put in place to protect employees
66

Baruch & Hudson, supra note 9, at 437.
Kathy L. Hudson, Prohibiting Genetic Discrimination, 356 NEW ENG. J.
MED. 2021, 2021-23 (2007). “At a recent congressional hearing, legislatures heard
testimony about a woman who underwent testing for the BRCA1 gene, using a false
name to keep her results private. Ovarian cancer later developed and her diagnosis
was delayed because her genetic-test result was not in her medical record.” Id.
68
Norris, supra note 48, at 200.
69
Id.
70
Hudson, supra note 67, at 2021-23.
71
Sismondo, supra note 38, at 466.
72
Slaughter, supra note 43, at 72.
73
Miller, supra note 22, at 251-57.
67
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from discrimination.74 But significant gaps remained, indicating
that American workers needed additional protection through
the use of uniform federal regulation.75
1. Americans with Disabilities Act
Prior to the passage of GINA, a worker experiencing
genetic information discrimination usually sought relief under
the Americans with Disabilities Act of 1990 (ADA). The ADA
provides protection from employment discrimination for
disabled employees that meet certain criteria.76 In order for an
employee to make a successful case under the ADA, the
employee must show that he or she is a “qualified individual
with a disability.”77 The ADA defines a “qualified individual
with a disability” as one who “with or without reasonable
accommodation, can perform the essential functions of the
employment position that such individual holds or desires.”78
The recently amended ADA also provides the courts with
guidelines for determining whether an employee is disabled,
defining “disability” as a “physical or mental impairment that
substantially limits one or more major life activities79 of such
individual; a record of such impairment; or being regarded as
having such an impairment.”80
In addition, the ADA limits certain employers from
requiring job candidates to provide medical information prior to
the extension of a job offer.81 Once an offer of employment has
74

Id. at 248-251, 259-263.
Id.
76
Americans with Disabilities Act, 42 U.S.C. §§ 12101-12117 (2006). “No
covered entity shall discriminate against a qualified individual with a disability
because of the disability of such individual in regard to job application procedures, the
hiring, advancement, or discharge of employees, employee compensation, job training,
and other terms, conditions, and privileges of employment.” Id. § 12112(a).
77
Id.
78
Id. § 12111(8).
79
Id. § 12102(2). A “major life activity” includes but is not limited to “caring
for oneself, performing manual tasks, seeing, hearing, eating, sleeping, walking,
standing, lifting, bending, speaking, breathing, learning, reading, concentrating,
thinking, communicating, and working.” ADA Amendments Act of 2008, Pub. L. No.
110-325, 122 Stat. 3553, § 4(a)(3)(2)(A) (codified in scattered sections of 29 and 42
U.S.C.).
80
ADA Amendments Act of 2008, § 4(a)(3). “An individual meets the
requirement of ‘being regarded as having such an impairment’ if the individual
establishes that he or she has been subjected to an action prohibited under this Act
because of an actual or perceived physical or mental impairment whether or not the
impairment limits or is perceived to limit a major life activity.” Id. § 4(a)(3)(A).
81
42 U.S.C. § 12112(d)(2)(A).
75
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been given, however, the employer can require that the
employee undergo a medical examination.82 If an employer
requires such an exam, the requirement must apply to all job
applicants equally, and the medical “inquiries must be jobrelated and consistent with a business necessity.”83
While the ADA will protect an employee who develops a
genetically related illness when it begins to substantially limit
a major life activity,84 this standard can be difficult to prove
and, in many situations, plaintiffs with genetic disorders will
not fit within the ADA provisions.85 For example, in Murphy v.
United Parcel Service, the plaintiff suffered from hypertension,
a condition which can be dependent both upon a person’s
genetic makeup as well as the person’s lifestyle.86 The Court
found that the plaintiff could not assert a claim under the ADA
because he was not “regarded as” disabled; although the
plaintiff was found to be unqualified to work in one particular
job (as a mechanic),87 he was not substantially limited in the
major life activity of working in a broad class of occupations.88
In addition to difficulties of proof, the ADA does not
address whether an employee’s genetic information, which
indicates the likelihood of developing a future disease, can
constitute a bona fide disability.89 To clarify the position of the
federal government, the United States Equal Employment
Opportunity Commission (“EEOC”) published guidelines
indicating that the government’s interpretation of the ADA
prohibits employment discrimination based on an individual’s

82

Id. § 12112(d)(3).
Jungreis, supra note 1, at 235 (citing 42 U.S.C. § 12112(d)(4)(A)).
84
Harris v. H & W Contracting Co., 102 F.3d 516, 524 (11th Cir. 1997).
Plaintiff suffered from Graves’ Disease, an “endocrine disorder affecting the thyroid
gland.” Id. at 517. Plaintiff suffered a panic attack and illness following an overdose of
her medication. Id. at 518. The court held that this genetic disease is covered by the
ADA. Id. at 524; see also Arnold v. United Parcel Service, Inc. 136 F.3d 854, 866 (1st
Cir. 1998) (holding that a plaintiff may make out a discrimination claim under the
ADA for diabetes mellitus).
85
Murphy v. United Parcel Service, Inc., 527 U.S. 516, 525 (1999).
86
Id. at 519.
87
Id. “A person with a genetic predisposition may demonstrate that they are
substantially limited in the major life activity of working if the individual can prove
that their employer mistakenly believes that, due to the genetic anomaly, they are
unable to work in either a class of jobs or a broad range of jobs in various classes as
compared to the average person.” Miller, supra note 22, at 246.
88
Murphy, 527 U.S. at 525.
89
Mark S. Dichter & Sarah E. Sutor, The New Genetic Age: Do Our Genes
Make Us Disabled Individuals Under the Americans with Disabilities Act?, 42 VILL. L.
REV. 613, 620 (1997).
83
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genetic makeup.90 In particular, the EEOC’s guidelines argue
that discrimination resulting from genetic testing is covered by
the disability definition prong of the ADA because it constitutes
“being regarded as having an impairment.”91 Along with the
EEOC’s interpretive guidance, several court decisions suggest
that an “employer’s concerns for an employee’s future
productivity, health insurance costs, and attendance fall within
the ‘regarded as’ prong of the ADA.”92 In its interpretative
memoranda, the EEOC provides a hypothetical that describes
an employer who retracts a job offer upon learning that the
applicant is genetically predisposed to develop colon cancer in
the future.93 Under this scenario, the EEOC argues that the
candidate should receive anti-discrimination protection under
the ADA.94 However, EEOC guidelines are merely persuasive
and, in the past, the U.S. Supreme Court has not been swayed
by the EEOC’s recommendations.95
Although the Supreme Court has never ruled on the
specific issue of whether the ADA protects an employee from
discrimination if genetic testing indicates a predisposition for
disease, the holding in Chevron U.S.A., Inc. v. Echazabal
suggests that such information does not fall under the ADA’s
disability provisions.96 In Echazabal, the employer refused to
hire the plaintiff because the company’s required physical
90

See U.S. EEOC, COMPLIANCE MANUAL, § 902 (1995).
Id.
92
Miller, supra note 22, at 240; see Jones v. Inter-County Imaging Ctrs., 889
F. Supp. 741, 742, 745 (S.D.N.Y. 1995) (denying defendant employer’s summary
judgment motion to plaintiff’s ADA claim alleging that he was terminated because
defendant believed that his sickle-cell condition would adversely affect future work
attendance). The sickle cell trait originates through inheritance of an unstable
hemoglobin variant (Hb S). HARRISON’S PRINCIPLES OF INTERNAL MEDICINE 1518
(Anthony S. Fauci et al. eds., 17th ed. 2008). The abnormality occurs almost exclusively
in persons of color. About eight percent of African-Americans are heterozygous for Hb
S. Id. “Although the genetic abnormality may give rise to congenital hemolytic anemia,
Hb S carriers generally have minimal clinical problems.” Miller, supra note 22, at 225
n.121.
93
U.S. EEOC, supra note 90, § 902.
94
Id.
95
Sutton v. United Airlines, 527 U.S. 471, 482 (1999). The Supreme Court
disagreed with the EEOC interpretation of the ADA that employees are to be evaluated
in their “hypothetical uncorrected state,” and held that plaintiffs suffering correctible
disabilities like vision impairment cannot make out a claim under the ADA. Id. The
level of deference the Supreme Court will accord to EEOC guidelines “will depend upon
the thoroughness evident in its consideration, the validity of its reasoning, its
consistency with earlier and later pronouncements, and all those factors which give it
power to persuade.” Gen. Elec. Co. v. Gilbert, 429 U.S. 125, 141-42 (1976).
96
Chevron U.S.A. Inc., v. Echazabal, 536 U.S. 73, 87 (2002); see Jungreis,
supra note 1, at 238.
91
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examination showed that the plaintiff had liver damage from
Hepatitis C.97 The employer’s doctors said that the condition
would be exacerbated by the exposure to toxins that were
widespread at the employer’s refinery.98 Indeed, the employer
“wish[ed] to avoid time lost to sickness, excessive turnover from
medical retirement or death, litigation under state tort law,
and the risk of violating the national Occupational Safety and
Health Act of 1970.”99 To uphold the employer’s policy, the
Court broadened its interpretation of the “direct threat to
others” defense and allowed this type of testing to continue if it
prevents threats to the health of individual employees.100
Arguably, this expanded reading of defenses to an ADA claim
could also allow genetic test results to be used in employment
decisions.101
The Seventh Circuit Court of Appeals has similarly
indicated that the use of genetic information to withhold
employment from applicants is permitted under the ADA.102 In
EEOC v. Rockwell International, seventy-two job applicants
were rejected by the employer based on their poor performance
on nerve conduction tests administered as part of the
application process.103 Although the applicants did not suffer an
impairment at the time of the examination, the employer
believed that the results of the tests indicated that these
applicants were likely to develop carpal tunnel syndrome in the
future.104 The court found that the ADA had not been violated
since the job applicants were not currently disabled, nor were
they mistakenly perceived to be currently disabled by the

97
98
99
100
101
102
103
104

Chevron, 536 U.S. at 76.
Id.
Id. at 84.
Id. at 78-79.
Jungreis, supra note 1, at 238.
EEOC v. Rockwell Int’l Corp., 243 F.3d 1012, 1017 (7th Cir. 2001).
Id. at 1014.
Id. In Rockwell, the employer described the genetic testing as follows:

The tests were designed . . . to confirm the presence of neuropathy—a
syndrome characterized by, among other things, sensory loss and muscle
weakness. . . . Rockwell sent each applicant to a medical facility where the
median nerves in his or her arms were stimulated with electric shocks and
the travel time of the electrical impulse from the shock points to the muscles
was recorded. The results of the test were given to Rockwell, which used
them in making personnel decisions.
Id.
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employer.105 Consequently, this case indicates a likelihood that
courts will not be afraid to dismiss discrimination claims
brought under the ADA when employers use genetic
information to predict the future health of job applicants.
In contrast to Echazabal and Rockwell, Bragdon v.
Abbott suggests the possibility that the ADA could afford
protection
from
discrimination
based
upon
genetic
predispositions for diseases.106 In Bragdon, the Supreme Court
found that the plaintiff’s HIV infection, though asymptomatic,
substantially limited the major life activity of reproduction
because it would impose a serious risk of infection to her sexual
partner and her future offspring.107 Miller notes that
“asymptomatic HIV is a physical impairment from the moment
of infection due to ‘the immediacy with which the virus begins
to damage the infected person’s blood cells and the severity of
the disease.’”108 While the Court recognized that an individual
infected with HIV remained capable of reproduction,
reproduction was regarded as dangerous to the public health,
and “[w]hen significant limitations result from the impairment,
the definition [of disability] is met even if the difficulties are
not insurmountable.”109
A parallel can be drawn between individuals with a
presently asymptomatic condition that will eventually progress
to a serious deterioration of the immune system and those who
are predisposed to a genetic disorder but currently show no
evidence of the disease.110 The latter are therefore also arguably
105

Id. at 1012. In a similar case decided that same year, the EEOC chose to
settle. EEOC v. Burlington N. Santa Fe R.R., No. 02-C-0456, 2002 WL 32155386, at *1
(E.D. Wis. May 8, 2002) (Agreed Order). Here the employer was also testing for a
genetic condition that causes carpal tunnel syndrome. Id. The employer “additionally
threatened one employee with termination when they refused to comply. According to
the EEOC, the genetic tests were unlawful under the ADA because they were not jobrelated, and conditioning employment on genetic test results constituted disability
discrimination.” Norris, supra note 48, at 203-04.
106
See Bragdon v. Abbott, 524 U.S. 624, 644-45 (1998).
107
Id. at 639-40.
108
Miller, supra note 22, at 242 (quoting Bragdon, 524 U.S. at 637).
109
Bragdon, 524 U.S. at 641.
110
Miller, supra note 22, at 243. Miller noted:
Science may be able to demonstrate that many asymptomatic genetic
disorders, while not resulting in any visible symptoms or characteristics, may
create abnormalities in an individual’s body systems or changes on a cellular
level as was shown with asymptomatic HIV. . . . Should a plaintiff be able to
demonstrate that the genetic condition causes some abnormality in the
person’s body, even on a molecular level, the condition would constitute a
physical impairment for ADA purposes.
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protected by the ADA under Bragdon. In addition, it could be
argued that some genetic predispositions, although
asymptomatic, limit a major life activity, as seen in Bragdon.111
However, there is clearly disagreement and a lack of clarity
between the outcome of Bragdon and the reasoning applied in
cases such as Chevron, Murphy, and Rockwell.112 As a result,
federal legislation separate from the ADA that specifically
addressed the growing field of genetic testing was necessary to
provide adequate protection for employees in the workplace. As
a practical matter, it had also been extremely difficult for
plaintiffs to win ADA cases.113 In 1999, the American Bar
Association Commission on Mental and Physical Disability
Law reported that defendant employers won 291 cases in the
federal court system, while only 13 plaintiff employees
prevailed.114 Consequently, GINA was a necessary reform to
give employees a chance to fight genetic information
discrimination in the workplace.
2. Title VII of the Civil Rights Act of 1964
Like the ADA, Title VII of the Civil Rights Act of 1964
(“Title VII”) provides minimal relief to those suffering adverse
employment actions because of their predisposition to genetic
disease.115 Title VII is limited to barring employment
discrimination on the basis of race, color, religion, sex, or
national origin.116 While several genetic diseases do correlate
with race, sex, and national origin, they are not solely
dependent upon these characteristics.117
Under Title VII, employees can prevail on a claim if
they establish that the employer singled out a specific

Id. at 243-44.
111
See Bragdon, 524 U.S. at 637.
112
See Chevron U.S.A. Inc. v. Echazabel, 536 U.S. 73 (2002); Murphy v.
United Parcel Serv., Inc., 527 U.S. 516 (1999); EEOC v. Rockwell, 243 F.3d 1012 (7th
Cir. 2001).
113
Marisa Anne Pagnattaro, Genetic Discrimination and the Workplace:
Employee’s Right to Privacy v. Employer’s Need to Know, 39 AM. BUS. L.J. 139, 165
(2001).
114
Id.; see also Claudia MacLachlan, Employers Winning ADA Suits: ABA
Study Shows Employees Won Only 13 Cases in 1999, NAT’L L.J., July 31, 2000. “That
means that ‘employers won 95.7% of the time,’ an increase over the 1998 survey
results.” Id.
115
Jungreis, supra note 1, at 239.
116
42 U.S.C. § 2000e-2(a) (2006).
117
Jungreis, supra note 1, at 239.
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protected class for genetic testing.118 In Norman-Bloodsaw v.
Lawrence Berkely Laboratory, the employer forced its black
female employees to undergo genetic testing for sickle cell
anemia, syphilis, and pregnancy.119 In that case, the plaintiffs’
claims were deemed valid because the court found
discrimination based on race and sex, both protected classes
under Title VII.120
However, if all employees of the lab had been required
to undergo genetic testing, there would not have been a
successful Title VII disparate treatment claim since each
employee would have been treated equally.121 A disparate
impact claim might be possible if, for example, a
disproportionate number of black employees tested positive for
sickle cell anemia and then suffered adverse employment
actions.122 However, it is clear that Title VII can only be applied
to genetic information discrimination under a very narrow set
of circumstances.123 As with the ADA, the scant coverage
provided by Title VII indicated to Congress the need for
separate federal legislation that would specifically target
employment discrimination on the basis of genetic
predisposition to disease.
3. Executive Order on Genetic Discrimination
Based on the inability of the ADA and Title VII to
provide employees with protection from discrimination on the
basis of their genetic information, President Clinton saw a need
for increased safeguards against discriminatory behavior in the
workplace.124 On February 8, 2000, he issued Executive Order
13,145, To Prohibit Discrimination in Federal Employment
Based on Genetic Information (the “Executive Order”).125 The
118

Norman-Bloodsaw v. Lawrence Berkely Lab., 135 F.3d 1260, 1272 (9th Cir.

1998).
119

Id. at 1265.
Id. at 1272.
121
See generally ROBERT BELTON ET AL., EMPLOYMENT DISCRIMINATION LAW:
CASES AND MATERIALS ON EQUALITY IN THE WORKPLACE ch. 4 (7th ed. 2004).
122
See generally id.
123
See generally id.
124
Miller, supra note 22, at 248.
125
Exec. Order No. 13,145, 65 Fed. Reg. 6,875 (Feb. 8, 2000) [hereinafter
Exec. Order No. 13,145], available at http://eeoc.gov/eeoc/history/35th/thelaw/
13145.html. The purpose of this Order is as follows:
120

Executive Order 13145 is intended to ensure that Executive branch
applicants and employees are judged on their current ability to perform the
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Executive Order targeted departments and agencies of the
federal government by limiting their access to, and use of, their
employees’ genetic information.
The Executive Order prohibits federal departments and
agencies from taking adverse employment actions based on an
employee’s “protected genetic information.”126 This “protected
genetic information” is defined in the Executive Order as “(1)
information about an individual’s genetic tests; (2) information
about the genetic tests of an individual’s family members; or (3)
information about the occurrence of a disease, or medical
condition or disorder in family members of the individual.”127
The Executive Order makes clear that the federal government
is barred from making employment decisions based upon a
worker’s predisposition to disease, medical condition, or other
physical disorder that does not impact his or her ability to
currently carry out the responsibilities of the position.128
Likewise, under the Executive Order, federal employers are
also prohibited from mandating genetic tests as a condition of
employment,129 including hiring and receiving benefits,
evaluating ability to perform the job, and classifying employees
in a discriminatory manner leading to lost job advancement
opportunities.130
In most instances, the Executive Order demands that
genetic information be kept confidential and removed from
jobs they seek or hold, and not on the possibility that they might, some day,
develop a disease or condition. Accordingly, the Executive Order places
stringent limits on the collection, use, and disclosure of protected genetic
information.
U.S. EEOC, POLICY GUIDANCE ON EXECUTIVE ORDER 13145: TO PROHIBIT
DISCRIMINATION IN FEDERAL EMPLOYMENT BASED ON GENETIC INFORMATION,
http://www.eeoc.gov/policy/docs/guidance-genetic.html.
126
Exec. Order No. 13,145, supra note 125, at 6877.
127
Id. “Information about an ‘individual’s current health status (including
information about sex, age, physical exams, and chemical, blood, or urine analyses) is
not protected genetic information’ unless it falls within one of the above categories.”
Pagnattaro, supra note 113, at 157.
128
Exec. Order No. 13,145, supra note 125, at 6877.
129
Id.
130
Id. Disclosure of such information is warranted only in the following
circumstances:
(1) to the employee; (2) to a person conducting research that complies with 45
C.F.R. Part 46, which concerns research involving human subjects; (3) if
required by federal law; (4) in response to a congressional subpoena or order
from a court with competent jurisdiction; or (5) to Executive branch officials
investigating compliance with the Executive Order.
Id.
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personnel files that can be easily accessed. However, the
Executive Order does provide federal employers some leeway to
require family medical information from prospective employees
who have already received conditional employment offers.131
Such information is only to be used for the purpose of
determining whether an applicant needs additional testing to
diagnose an existing disease or health condition that could
prevent the individual from fulfilling his or her current job
responsibilities.132 The results of these tests may only be viewed
by medical personnel in charge of assessing whether the
applicant must undergo additional medical testing.133
Although the Executive Order expands the rights of
federal employees beyond the ADA and Title VII, it leaves out
the large number of Americans who are not employed by the
federal government. Therefore, the vast majority of Americans
still required legislation that prevented private employers from
using their employees’ genetic information as a means for
discriminatory behavior.
4. Constitutional Privacy Rights and the Privacy Act of
1974
Another source of potential protection against genetic
discrimination in the workplace is the Fourteenth Amendment
of the U.S. Constitution. Indeed, some courts have held that an
individual has the right to keep personal health information
private and, therefore, employees should be protected against
genetic information discrimination under the Fourteenth
Amendment.134 For example, in United States v. Westinghouse
Electric Corp., the Third Circuit Court of Appeals stated that
there is “no question that an employee’s medical records, which
may contain intimate facts of a personal nature, are well
within the ambit of materials entitled to privacy protection.”135
The court held that “[g]enetic information should thus be
protected pursuant to the right to privacy under the United
States Constitution.”136

131

Id.
Id.
133
Id. at 6879.
134
This applies only to state actors (government employers). Miller, supra
note 22, at 251.
135
U.S. v. Westinghouse Elec. Corp., 638 F.2d 570, 577 (3d Cir. 1980).
136
Miller, supra note 22, at 251.
132
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Similarly, the Supreme Court has found that, in certain
situations, the government does have an obligation under the
Fourteenth Amendment to avoid disclosing private
information.137 However, the Court has provided little guidance
as to when such situations will arise. In Whalen v. Roe,
patients requiring Schedule II drugs (the most dangerous of
legitimate prescription medications) declined treatment due to
their concern that the computerized records would stigmatize
them as drug addicts.138 Furthermore, doctors worried that they
could not adequately treat their patients without privacy
protection for their records.139 While the Court was “not
unaware of the threat to privacy implicit in the accumulation of
vast amounts of personal information in computerized data
banks,” it did not find a violation of “any right or liberty
guaranteed” by the Fourteenth Amendment.140
More pointedly, the Ninth Circuit Court of Appeals
specifically addressed the issue of whether privacy rights apply
to genetic information in Norman-Bloodsaw v. Lawrence
Berkeley Laboratory.141 In Norman-Bloodsaw, the employer
conducted genetic testing for syphilis, pregnancy, and sickle
cell anemia during routine mandatory medical exams, but
without the authorization of the employees.142 The plaintiffs
challenged these practices as violations of both the ADA and
Title VII and alleged that under the U.S. Constitution, their
rights to privacy and due process had been denied.143 The court
determined that administering genetic tests without the
consent of an employee was a clear violation of that employee’s
right to privacy.144 In addition, the court found that “the

137
138
139
140
141

Whalen v. Roe, 429 U.S. 589, 605 (1977).
Id. at 595.
Id. at 604.
Id. at 605-06.
Norman-Bloodsaw v. Lawrence Berkeley Lab., 135 F.3d 1260, 1269 (9th

Cir. 1998).
142

Id. at 1264-65.
Id. at 1265. While granting relief on the constitutional claims, the court
“dismiss[ed] . . . the ADA claims on the following grounds: (1) that no job related action
was taken against the plaintiffs as a result of the testing; (2) the lack of evidence of
inadequate safeguards to protect the confidentiality of the information; and (3) the
scope of exams did not violate the statute.” Miller, supra note 22, at 253. For a
discussion of the outcome of the Title VII claims see supra Part II(C)(2).
144
Miller, supra note 22, at 253; see Norman-Bloodsaw, 135 F.3d at 1269.
143
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performance of these tests, without explicit notice and informed
consent, violates prevailing medical standards.”145
Even if the Supreme Court eventually holds that genetic
information testing requires protection under the Fourteenth
Amendment, federal constitutional privacy interests can still
be challenged. Under this analysis, privacy rights “must be
balanced against the [federal and/or state] government
employer’s legitimate interest in collecting the information.”146
Thus, if a government employer can put forth a valid reason for
requiring genetic information from their employees, the courts
will not infringe upon these practices, even if they result in
discriminatory behavior.147
An additional modicum of protection for employees may
be found in the Privacy Act of 1974 (the “Privacy Act”).148 The
Privacy Act regulates the collection and use of records by
federal agencies and limits their access to information
“relevant and necessary” to their purpose.149 Under the Privacy
Act, one is allowed to access his or her personal records on
request and seek amendment to his or her file if it is
inaccurate.150 Finally, the Act limits disclosure of records to
outside parties.151
The holdings of Whalen and Norman-Bloodsaw suggest
that the Supreme Court is likely to find, in some situations,
that employees’ genetic test results should be shielded from an
employer.152 In these limited situations, employees would be
protected from discrimination since their employer would not
have access to genetic information indicating that they are
predisposed to develop a disease in the future.153 However, these
rights can be limited if the government employer can show a
legitimate
interest
in
obtaining
the
information.154
145

Miller, supra note 22, at 253 (internal quotation marks omitted) (quoting
Norman-Bloodsaw, 135 F.3d at 1267).
146
Id. at 251.
147
Id. at 253.
148
5 U.S.C. § 552(a) (2006). “Like the federal Constitution, however, it applies
to only government action, particularly, the disclosure of information obtained by a
government agency.” Miller, supra note 22, at 253; see Norman-Bloodsaw, 135 F.3d at
1269.
149
Miller, supra note 22, at 253 (citation omitted) (internal quotation marks
omitted).
150
Id. at 253-54.
151
Id. at 254.
152
Norman-Bloodsaw, 135 F.3d at 1269.
153
Miller, supra note 22, at 253.
154
Id.
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Furthermore, since these protections only apply to federal
employees, those working in the private sector will be barred
from making similar claims.155 Consequently, GINA was
required to provide a litigation outlet for the majority of
employees.
5. The Health Insurance Portability and Accountability Act
Limited protection from genetic discrimination in health
insurance access is also provided by the Health Insurance
Portability and Accountability Act of 1996.156 However, like the
legislation previously discussed, HIPAA does not provide
sufficient protection against genetic discrimination in the
workplace. Since many Americans participate in group health
insurance through their employers, HIPAA has become
intertwined with workers’ rights issues.157 HIPAA bars group
health insurance plans from abusing their access to
participants’ genetic information to deny continued eligibility
in the plan.158 In most cases, HIPAA enables individuals to
receive insurance coverage even if they have prior or current
medical conditions and it allows employees to retain coverage if
they switch jobs or insurance providers.159 Most significantly,
under HIPPA, genetic information alone cannot constitute a
preexisting condition or a means for excluding a covered
employee.160 Therefore, a member of a group health insurance
plan who discovers that he has a gene that may predispose him
to a disease will not be denied coverage if the plan is covered by
HIPAA.161
Although HIPAA took the first steps toward directly
targeting genetic discrimination, the statute is not sufficient.162
While HIPAA prevents health care providers from increasing
the cost of an individual’s insurance in a discriminatory
manner, insurance companies are not barred from raising an
155

Id.
29 U.S.C. § 1181 (2006).
157
Miller, supra note 22, at 255.
158
29 U.S.C. § 1181(d)(1).
159
Miller, supra note 22, at 255.
160
Id.
161
Miller, supra note 22, at 255. “In addition, coverage cannot be denied for a
newborn or newly adopted child’s medical condition, as long as the child is enrolled
within thirty days of birth or adoption, and benefits for the medical condition are
otherwise available under the plan.” Id.
162
Norris, supra note 48, at 204-05.
156
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employer’s group premium based on the genetic makeup of its
employees.163 Furthermore, HIPAA does not apply to
individuals or the self-employed seeking health insurance
independently; nor does it prohibit health care providers from
denying coverage to these individuals outright.164 This gap in
HIPAA affects approximately 10-15% of people who purchase
health insurance individually.165 Finally, even though HIPAA
bars insurers from rescinding policies to a small employer due
to the genetic information of an enrollee, the same rule does
not apply to larger employers.166
Like prior attempts at regulation, the gaps in HIPAA,
which allow for genetic information discrimination to occur,
indicate that specific reform was needed to provide protection
to employees.
6. State Law Protecting Against the Misuse of Genetic
Information by Employers
The abuse of genetic information in employment was
first addressed by state legislatures in the 1970s and 1980s
through the creation of protective provisions for workers with
the genetic marker for sickle cell anemia.167 Some of the first
states to enact such statutes were Florida, Louisiana, and
North Carolina.168 In 1981, New Jersey followed suit and
banned employment discrimination based on a worker’s genetic
predisposition for “sickle cell anemia, hemoglobin C,
thalassemia, Tay Sachs, or cystic fibrosis.”169 Currently, thirtyfour states and the District of Columbia have enacted
legislation barring genetic discrimination in decisions
regarding hiring, firing, and/or determining the terms,
conditions or privileges of employment.170 However, there is
great variation in the scope and application of these laws. For
those that provide some level of protection for employees,
163

Id. at 205.
See 29 U.S.C. § 1181.
165
Norris, supra note 48, at 205.
166
Id.
167
NAT’L CONFERENCE OF STATE LEGISLATURES, GENETIC EMPLOYMENT LAWS
(2008) [hereinafter NAT’L CONFERENCE], available at http://www.ncsl.org/
IssuesResearch/Health/GeneticEmploymentLaws/tabid/14280/Default.aspx.
168
Id.
169
Mark A. Rothstein, Is GINA Worth the Wait?, 36 J.L. MED. & ETHICS 174,
175 (2008).
170
NAT’L CONFERENCE, supra note 167.
164
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twenty-five states prohibit employers from requiring genetic
testing, eighteen prohibit employers from requesting genetic
test results, and sixteen prohibit employers from performing
their own genetic testing in the workplace.171 Only eleven states
outright ban employers from obtaining the genetic test results
of their workers.172
While it now appears that protections provided by states
are on the rise, prior to the enactment of GINA, residents of
fifteen states were left with only the bare-bones federal
protection discussed earlier. Moreover, a system reliant solely
on state law has proven difficult to administer since the
various protections offered by each state unnecessarily burden
multi-state employers with a grab-bag of state rules and
regulations.173 Furthermore, prior to uniform federal regulation,
employees continued to fear genetic testing despite local
protections.174 If workers chose to relocate to a state that lacked
similar legislation regarding genetic information, it would be
too risky to have potentially harmful information in their
medical records.175
III.

NEW PROTECTIONS PROVIDED BY GINA

After almost thirteen years of consideration by
Congress, GINA passed, filling in the gaps in federal law and
providing protection to the American workforce.176 On May 21,
2008, President George W. Bush signed GINA into law,177 and it
went into effect on November 21, 2009.178 As the first civil rights
legislation of the twenty-first century,179 “GINA represents
significant progress in protecting civilians from genetic
discrimination in employment and health insurance.”180
171

Id.
Id. In addition, only fourteen states have created specific penalties for
genetic discrimination in employment. Id.
173
Jungreis, supra note 1, at 233.
174
Id.
175
Id.
176
Baruch & Hudson, supra note 9, at 435.
177
Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233,
122 Stat. 881.
178
Id. § 213.
179
Hudson et al., supra note 15, at 2662.
180
Baruch & Hudson, supra note 9, at 437. “[W]hen it finally overcame the
opposition of a few members of Congress who controlled the rules of the House and
Senate for many years, it passed almost unanimously, with strong bipartisan support.”
Id. at 435.
172
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Significantly, GINA was drafted to target both
employers and health care providers. Title I targets genetic
information discrimination in health insurance benefits and
group health plans.181 In particular, it “prohibits the use of
genetic information to set health insurance premiums, deny
coverage, or affect employment.”182 More specifically, GINA
“prohibits group and individual health insurers from using a
person’s genetic information in determining eligibility or
premiums; prohibits an insurer from requesting or requiring
that a person undergo a genetic test; and prohibits employers
from using a person’s genetic information about persons or
their family members.”183 Title I applies to all ERISA group
health plans, group market insurers, individual market
insurers, Medicare supplemental insurers, and non-federal
governmental plans.184
Title II of the Act applies specifically to genetic
discrimination in employment.185 This title pertains to
employers, employment agencies, and labor organizations.186
Under GINA, it is unlawful for employers to make hiring and
firing decisions based on employees’ genetic information.187
Furthermore, the statute prohibits employers from using
genetic information to take discriminatory actions regarding
compensation, benefits, or other terms and conditions of
employment.188 In addition, an employer is also barred from
segregating or classifying employees in a manner that would
deprive them of employment opportunities or adversely affect
their employment status because of genetic data.189
In addition to proscribing genetic discrimination, GINA
also prohibits employers from requesting, requiring, or
purchasing genetic information of an employee or from family
members of the employee.190 However, the Act does provide six

181

GINA, H.R. 493, 110th Cong. (2008).
Allison, supra note 7, at 596.
183
Hudson et al., supra note 15, at 2662.
184
Nuffort, supra note 41, at 12.
185
GINA, H.R. 493.
186
GINA, § 201(a)(2)(B); id. § 201(C). “Covered employees” (including an
applicant) are those defined in section 701(f) of the Civil Rights Act of 1964 (42 U.S.C.
§ 2000e(f)). Id.
187
Id. § 202(a)(1).
188
Id.
189
Id. § 202(a)(2).
190
Id. § 202(b).
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exceptions to this rule.191 First, there is no unlawful
employment practice when an employer makes an inadvertent
mistake requesting family medical history.192 Likewise, there is
also no violation when an employee provides voluntary, written
authorization for employers to obtain family genetic
information.193 In addition, employers may request family
medical information in order to comply with the Family
Medical Leave Act of 1993 or similar state laws.194 Employers
may also purchase commercially and publically available
documents that contain family medical information of an
employee.195 An employer may also require genetic information
if it is to be used for genetic monitoring of the biological effects
of toxic substances in the workplace.196 To fall within this
exemption, the employer must provide written notice to the
employee, obtain voluntary and written authorization from the
employee, and keep the employee informed of individual
monitoring results.197 Such monitoring must also be required by
Federal or State law, and must be in compliance with the
Occupational Safety and Health Act of 1970.198 Lastly, the
genetic monitoring results must be received in the aggregate
and cannot identify individual employees.199 Finally, GINA also
provides an exception when an employer must conduct DNA
analysis for law enforcement purposes or when it is necessary
to identify human remains.200
GINA provides definitions for key terms such as
“genetic information,” “genetic services,” and “genetic test.”201
191

Id. § 202(b)(1)-(6).
Id. § 202(b)(1).
193
Id. § 202(b)(2).
194
Id. § 202(b)(3).
195
Id. § 202(b)(4). Employers may consult newspapers, magazines, periodicals,
and books, but cannot use medical databases or court documents to obtain genetic
information of an employee.
196
Id. § 202(b)(5).
197
Id. § 202(b)(5)(A); id. § 202(b)(5)(B)(i); id. § 202(b)(5)(C).
198
Id. § 202(b)(5)(B)(ii); id. § 202(b)(5)(D).
199
Id. § 202(b)(5)(E).
200
Id. § 202(b)(6).
201
Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233,
122 Stat. 881. “Genetic information” is:
192

information about genetic tests, the genetic tests of family members, and the
manifestation of a disease or disorder in family members (a ‘family member’
is defined as a first-, second-, third-, or fourth-degree relative). It also
includes any request for, or receipt of, genetic services, or participation in
clinical research that includes genetic services, by an individual or his or her
family members. ‘Genetic services’ may include a genetic test, genetic
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Examples of genetic tests that will now be protected under
GINA include, but are not limited to, the following: “tests for
BRCA1/ BRCA2 (breast cancer) or HNPCC (colon cancer)
mutations; classifications of genetic properties of an existing
tumor to help determine therapy; tests for Huntington disease
mutations; carrier screenings for disorders such as cystic
fibrosis, sickle cell anemia, spinal muscular atrophy, and the
fragile X syndrome.”202
Several federal agencies have been charged to enforce
GINA, including the Department of Health and Human
Services, the Department of Labor, and the Department of
Treasury, along with the EEOC.203 In addition, GINA mandates
that a Genetic Nondiscrimination Study Commission be formed
by May 2015.204 This new Commission will review scientific
advancements in genetics and advise Congress as to the
potential need to amend GINA to include disparate impact
causes of action.205 The Commission will be comprised of eight
members and will be located in a facility within the EEOC.206
During deliberations, members of Congress determined
that the imposition of harsher penalties for violations of GINA
would be illogical and unreasonable if they exceeded the
counseling (including obtaining, interpreting, or assessing genetic
information), or genetic education. The law states specifically that genetic
information does not include information about sex or age. Further
clarification about the scope of these definitions is expected through the
federal regulatory process, currently under way. The definition of ‘genetic
test’ is quite specific. Under GINA, genetic test means an analysis of human
DNA, RNA, chromosomes, proteins, or metabolites to detect genotypes,
mutations, or chromosomal changes. However, according to the law, genetic
test does not include ‘(i) an analysis of proteins or metabolites that does not
detect genotypes, mutations, or chromosomal changes; or (ii) an analysis of
proteins or metabolites that is directly related to a manifested disease,
disorder, or pathological condition that could reasonably be detected by a
healthcare professional with appropriate training and expertise in the field of
medicine involved. It is important to note that (ii) does not appear in the
employment section of the law- in the workplace, this exception to the
definition of genetic test would not apply. In other words, GINA does not
prohibit insurers from underwriting based on information that reveals
information about current health status. However, employers may not use
such information to make employment decisions.
Baruch & Hudson, supra note 9, at 438-39; Genetic Information Nondiscrimination Act
of 2008, Pub. L. No. 110-233, 122 Stat. 881.
202
Genetics & Pub. Policy Ctr., John Hopkins Univ., Information on the
Genetic Information Nondiscrimination Act (GINA) [hereinafter Information on GINA],
www.DNApolicy.org.
203
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204
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penalties for violating other employment laws such as the
ADA, Title VII, and HIPPA.207 It was felt that consistency would
ensure the bill’s passage and avoid overloading the burden on
health insurers and employers.208 However, remedies such as
corrective action and monetary awards are available to harmed
employees.209 In addition, citizens of states that have more
encompassing protection under state law than under GINA will
still be able to bring state law claims if they suffer genetic
discrimination in the workplace.210
With GINA in effect, workers who suffer from adverse
employment action based on their employer’s knowledge of
their genetic predisposition to develop a disease will have a
claim and remedy under federal law.211 Significantly, plaintiff
employees no longer have to stretch the facts of their case to fit
within the regulatory framework of the ADA and Title VII,
which offer inadequate protection for genetic information
discrimination.212
IV.

WHAT GINA LEFT OUT AND THE PROTECTIONS
REQUIRED IN THE FUTURE

Despite the clear advantages that GINA provides to
employees
seeking
relief
from
genetic
information
discrimination in the workplace, the Act fails to provide
comprehensive protection. On the one hand, some remaining
gaps in the legislation are due to the fact that GINA sponsors
needed to make compromises for it to be passed.213 Other
weaknesses in the act are due to the rapid advancement of
clinical medicine and biotechnology.214
Critics of GINA argue that the act is too narrow and
limited in scope.215 For them, the Act “does not prevent health
207
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208
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211
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213
Baruch & Hudson, supra note 9, at 435. “GINA is, like most enacted laws,
a compromise and reflects a strategic and delicate balancing of interests of all key
stakeholders including providers, patients, insurers, employers, researchers, and
lawmakers.” Id.
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J. M. Appel, When the Boss Turns Pusher: A Proposal for Employee
Protections in the Age of Cosmetic Neurology, 34 J. MED. ETHICS 616, 618 (2008).
215
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care providers from recommending genetic tests to their
patients . . . , mandate coverage for any particular test or
treatment . . . , prohibit medical underwriting based on current
health status . . . , cover life, disability or long-term-care
insurance, [and does not] apply to members of the military.”216
With regard to employment issues in particular, GINA “does
not prohibit workplace collection of genetic information for
toxicity monitoring programs, employer-sponsored wellness
programs, administration of federal and state Family and
Medical Leave laws, and in certain cases of inadvertent
acquisition of information.”217
In the near future, courts may have to determine
whether employers can require DNA testing for criminal
background checks under GINA. Recently, the University of
Akron implemented a policy reserving the right “to require any
prospective faculty, staff, or contractor to submit a DNA
sample.”218 While employers typically conduct general
background checks during the hiring process, the Ohio school is
the first to take such extreme measures.219 The school
maintains that Akron’s goal is solely to sustain a safe
environment for students and staff and that “DNA testing was
included in the policy because there ha[s] been national
discussion that indicate[s] that in the future, reliance on
fingerprinting will diminish and DNA for criminal
identification will be the prominent technology.”220 Arguably,
GINA does not delineate a distinction between requiring
genetic information for discriminatory versus legitimate
purposes; likewise, the policy is not covered by one of the
exceptions mentioned above.221 Since one employee has already
quit in response to the school’s policy,222 this may lead to the
first opportunity for the courts to evaluate GINA’s reach.
GINA also fails to protect those who suffer from other
immutable characteristics that may indicate a likelihood of
developing an illness in the future, such as abnormalities found
216
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on a screening colonoscopy.223 Thus, an insurance company can
implement discriminatory coverage and pricing policies against
these individuals, even though it could not do so to persons
with a genetic predisposition for the condition.224
For many employees who believe that they should now
be protected, GINA stands to cause confusion since many
medical tests and examinations are not covered by the act.225
Routine screenings “such as complete blood counts (CBC, or
blood panel), cholesterol tests, and liver-function tests are not
protected under GINA.”226 This is problematic since cholesterol
levels, for example, can depend on a person’s genetic makeup
and thus cannot always be controlled by lifestyle choices.227 As a
potentially immutable characteristic, these patients should also
receive some form of protection against employer
discrimination. Other areas of concern include: “DNA analysis
of infectious agents such as bacteria, viruses, and fungi. An
HIV test, for example, is not covered. Although it is a
retrovirus that inserts itself into human DNA, HIV is not itself
human DNA and measuring its presence does not constitute a
genetic test under the law’s definition.”228 From these examples,
it is clear that there is a fuzzy line as to what constitutes a
genetic test. Arguably, GINA’s reach is too narrow and should
be expanded to encompass additional borderline traits such as
cholesterol.
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Given the short period of time that a plaintiff has to file
a complaint under GINA, many meritorious discrimination
suits will likely be dismissed on procedural grounds. As in Title
VII and ADA cases, employees have an obligation to exhaust
all administrative remedies before they can bring suit under
the act.229 Since the employment provisions of the legislation are
regulated by the EEOC, employees must seek a right-to-sue
letter from the agency within 90 days of the alleged
discriminatory employment action or they will forfeit their
right to bring a claim.230 Since a large number of eligible Title
VII and ADA claims are dismissed each year for plaintiffs’
failure to exhaust administrative remedies, typically because
the plaintiffs were unaware of the strict and extremely short
deadlines involved, it is likely that many legitimate allegations
of genetic discrimination will be dismissed for the same
procedural reasons.231
In addition to the gaps mentioned above, it is likely that
additional protective legislation for workers will be required as
biotechnology and medicine progress.232 Amendments to GINA
likely will be necessary in the near future to accommodate
rapid advancement in science. For example, many genetic tests
currently require improvements in order to increase accuracy
and effectiveness.233 While some tests are extremely precise,
such as the screen for Huntington’s disease,234 scientists are still
looking to advance the predictive performance of the test for
cardiovascular disease (CVD).235 While a gene variant has been
identified for CVD, using this information has not helped
geneticists to predict its occurrence.236 Out of a study of 22,129
women, “[a]dding the genotypic information to traditional risk
factors—including family history—reclassified 2.6% of the
women to different risk categories, but 63.4% of them were
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incorrectly reclassified.”237 Similar problems have occurred in
predictive studies for prostate cancer and Type 2 diabetes.238
However, research in this area is continuously evolving.
While other problems such as cost-effectiveness239 exist, it is
likely that these types of genetic tests will become more
accurate and more available for a host of diseases that may or
may not be covered by the current form of GINA.
Another example of an emerging scientific field with
genetic discrimination potential is neuro-pharmacological
enhancement, also referred to as “cosmetic neurology.”240
Potential developments in this field offer “the prospect of
improving the learning, memory, and attention skills of
healthy individuals, well beyond the normal human range.”241
The field of cosmetic neurology is fraught with scientific, legal,
and ethical concerns; yet, with regards to employment, new
forms of coercion and discrimination are feared.242 In particular,
many are worried that the abuse will target behavioral traits
such as limited attention span due to Attention Deficit
Hyperactivity Disorder (“ADHD”). While ADHD can be caused
by a range of factors including environmental agents, brain
injury, food additives, and sugar, genetics plays a large role.243
Indeed, “[s]tudies indicate that 25% of the close relatives in the
families of ADHD children also have ADHD, whereas the rate
is about 5% in the general population.”244
Although ADHD has a strong link to genetics, GINA
does not prevent employers from testing the memory skills or
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attention spans of their workers.245 Here, the danger stems from
the naturally unbalanced relationship that exists in at-will
employment situations: the employer enjoys a much better
bargaining position than his or her employees. Thus, workers
could feel compelled to consume enhancing drugs, such as
Adderral, to retain their jobs or to keep pace with those in the
workforce who choose to consume these pharmaceuticals.246
Eventually, this could result in discrimination, as separation
forms between those who consume neurological enhancers and
those who do not.247 While there certainly are situations where
such skills are necessary to perform a job, as the science of
pharmacology progresses, protections will be needed in the
form of acts like GINA to guard employees from the pressure to
medicate to maintain their positions.
CONCLUSION
Due to this country’s history of genetic discrimination,
the GINA was a necessary piece of legislation. Now that GINA
is in effect, Americans no longer need to fear potential
discrimination from their insurers and employers, and thus
will be more willing to take advantage of existing opportunities
for genetic testing.248 However, while GINA fills in some of the
gaps of prior federal legislation, the compromises made in its
passage leave unprotected many genetically-based categories of
illness.249 Furthermore, as medicine and technology inexorably
advance, it is also likely that amendments to GINA will be
required to continue to provide adequate protection to
individuals.250
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